Compare
Ilumya vs. Skyrizi

Ilumya (tildrakizumab or tildrakizumab-asmn) is used to treat plaque psoriasis in adults. It's a type of monoclonal antibody called an interleukin-23 antagonist. It works by lowering inflammation in the skin. This medication is given as an injection under the skin every 3 months by a healthcare professional. Some people might have upper respiratory tract infections as a side effect. Ilumya (tildrakizumab) is only available as a brand-name medication.

• Moderate-to-severe plaque psoriasis

• Upper respiratory infections (14%)

• Serious allergic reactions
• Higher risk of infections
• Avoid live vaccines

Skyrizi (risankizumab or risankizumab-rzaa) is an injection used to treat different inflammatory conditions in adults. This includes plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It belongs to the drug class called interleukin antagonists. It works to lower inflammation and relieve symptoms. After the first few doses, you usually get the Skyrizi (risankizumab) injection every 2 or 3 months. This medication can raise your risk of infection as a side effect.

• Moderate-to-severe plaque psoriasis in adults
• Psoriatic arthritis in adults
• Moderate-to-severe Crohn's disease in adults
• Moderate-to-severe ulcerative colitis in adults

• Upper respiratory infections (13%)
• Headache (4%)
• Tiredness (3%)

• Allergic reaction
• Risk of infection
• Rare case of liver injury
• Caution when getting vaccines